November 28, 2016 - By Louis Casey
In analysts report released on 28 November, Techfinancials Inc Ord Usd0.0005 Di (LON:TECH) stock had its Buy Rating maintained by equity research analysts at Northland Capital. They currently have a GBX 27.00 TP on firm. Northland Capital’s target suggests a potential upside of 63.64% from the company’s last stock close price.
About 93,674 shares traded hands or 1184.08% up from the average. TechFinancials Inc (LON:TECH) has risen 32.00% since April 28, 2016 and is uptrending. It has outperformed by 25.99% the S&P500.
Analysts await BIO-TECHNE Corp (NASDAQ:TECH) to report earnings on February, 7. They expect $0.79 earnings per share, down 3.66% or $0.03 from last year’s $0.82 per share. TECH’s profit will be $29.72 million for 33.91 P/E if the $0.79 EPS becomes a reality. After $0.78 actual earnings per share reported by BIO-TECHNE Corp for the previous quarter, Wall Street now forecasts 1.28% EPS growth.
Insitutional Activity: The institutional sentiment decreased to 0.97 in 2016 Q2. Its down 0.15, from 1.12 in 2016Q1. The ratio fall, as 15 funds sold all TechFinancials Inc shares owned while 93 reduced positions. 40 funds bought stakes while 81 increased positions. They now own 36.18 million shares or 1.56% less from 36.75 million shares in 2016Q1.
Confluence Invest Mngmt Ltd Llc has 0.07% invested in the company for 21,740 shares. Papp L Roy & Associates holds 0.18% of its portfolio in TechFinancials Inc (LON:TECH) for 6,945 shares. Denver Inv Advsrs Limited Liability reported 199,867 shares or 1.02% of all its holdings. First Light Asset Mngmt Ltd Company holds 1.26% of its portfolio in TechFinancials Inc (LON:TECH) for 24,146 shares. Eagle Asset Management, a Florida-based fund reported 32,060 shares. Bahl & Gaynor accumulated 5,490 shares or 0.01% of the stock. Comm Bancorp last reported 0.02% of its portfolio in the stock. City owns 20 shares or 0% of their US portfolio. Paloma Prtnrs Management last reported 10,966 shares in the company. Financial Bank Of Montreal Can holds 0% of its portfolio in TechFinancials Inc (LON:TECH) for 11,940 shares. The Texas-based 1St Advsrs has invested 0.08% in TechFinancials Inc (LON:TECH). Advisory Svcs Net Llc last reported 0% of its portfolio in the stock. Accredited Invsts Incorporated holds 2,100 shares or 0.07% of its portfolio. The New York-based Joel Isaacson Limited has invested 0% in TechFinancials Inc (LON:TECH). Glenmede Trust Comm Na last reported 0% of its portfolio in the stock.
Insider Transactions: Since June 15, 2016, the stock had 0 buys, and 10 selling transactions for $1.38 million net activity. $693,039 worth of TechFinancials Inc (LON:TECH) shares were sold by BAUMGARTNER ROBERT V. LUCAS ROGER C sold $10,471 worth of stock or 100 shares. Shares for $57,904 were sold by Gould Kevin S. $186,716 worth of TechFinancials Inc (LON:TECH) shares were sold by HIGGINS JOHN L.
TechFinancials Inc is a software developer, supplying a trading solution to online brokers through whom its software is used by traders across the world. The company has a market cap of 11.90 million GBP. The Firm supplies software and services to brokers in the binary options market and operates its own online broker, www.OptionFair.com. It has a 15.33 P/E ratio. The Company’s www.OptionFair.com enables the Company to trial and evaluate products that it has under development.
According to Zacks Investment Research, “Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits; and clinical diagnostic immunoassay kits. The Company also offers flow cytometry products; natural and synthetic chemical compounds; hematology controls and calibrators; and hematology control products. Bio-Techne Corporation, formerly known as Techne Corporation, is headquartered in Minneapolis, Minnesota.”
Bio-Techne Corporation, incorporated on July 17, 1981, develops, makes and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Firm operates through three divisions: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, makes and sells biotechnology research and diagnostic products across the world. The Clinical Controls segment develops and makes controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis.
Another recent and important TechFinancials Inc (LON:TECH) news was published by Uk.Finance.Yahoo.com which published an article titled: “TechFinancials, Inc. (TECH.L)” on March 27, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey